These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427 [TBL] [Abstract][Full Text] [Related]
3. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
4. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Akerman GS; Tolleson WH; Brown KL; Zyzak LL; Mourateva E; Engin TS; Basaraba A; Coker AL; Creek KE; Pirisi L Cancer Res; 2001 May; 61(9):3837-43. PubMed ID: 11325860 [TBL] [Abstract][Full Text] [Related]
6. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417 [TBL] [Abstract][Full Text] [Related]
7. The epithelial-mesenchymal transition induced by keratinocyte growth conditions is overcome by E6 and E7 from HPV16, but not HPV8 and HPV38: characterization of global transcription profiles. Azzimonti B; Dell'oste V; Borgogna C; Mondini M; Gugliesi F; De Andrea M; Chiorino G; Scatolini M; Ghimenti C; Landolfo S; Gariglio M Virology; 2009 Jun; 388(2):260-9. PubMed ID: 19398117 [TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939 [TBL] [Abstract][Full Text] [Related]
9. Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins. Harden ME; Prasad N; Griffiths A; Munger K mBio; 2017 Jan; 8(1):. PubMed ID: 28049151 [TBL] [Abstract][Full Text] [Related]
10. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Poláková I; Pokorná D; Dusková M; Smahel M Vaccine; 2010 Feb; 28(6):1506-13. PubMed ID: 20003917 [TBL] [Abstract][Full Text] [Related]
11. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene. Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833 [TBL] [Abstract][Full Text] [Related]
12. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Wick DA; Webb JR Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200 [TBL] [Abstract][Full Text] [Related]
13. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Richard C; Lanner C; Naryzhny SN; Sherman L; Lee H; Lambert PF; Zehbe I Oncogene; 2010 Jun; 29(23):3435-45. PubMed ID: 20383192 [TBL] [Abstract][Full Text] [Related]
14. [Induction of human oral carcinoma by human papillomavirus 16 E6/E7 and TPA]. Zhao J; Cao ZY; Sun YT; Liao QP; Du HJ; Zeng Y Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):234-6. PubMed ID: 15340565 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Smahel M; Poláková I; Pokorná D; Ludvíková V; Dusková M; Vlasák J Int J Oncol; 2008 Jul; 33(1):93-101. PubMed ID: 18575754 [TBL] [Abstract][Full Text] [Related]
16. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071 [TBL] [Abstract][Full Text] [Related]
17. High Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7. Aromseree S; Middeldorp JM; Pientong C; van Eijndhoven M; Ramayanti O; Lougheed SM; Pegtel DM; Steenbergen RD; Ekalaksananan T PLoS One; 2017; 12(1):e0169290. PubMed ID: 28056059 [TBL] [Abstract][Full Text] [Related]
18. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). Almajhdi FN; Senger T; Amer HM; Gissmann L; Öhlschläger P PLoS One; 2014; 9(11):e113461. PubMed ID: 25422946 [TBL] [Abstract][Full Text] [Related]
19. Identification of miRNAs dysregulated in human foreskin keratinocytes (HFKs) expressing the human papillomavirus (HPV) Type 16 E6 and E7 oncoproteins. Yablonska S; Hoskins EE; Wells SI; Khan SA Microrna; 2013; 2(1):2-13. PubMed ID: 25070710 [TBL] [Abstract][Full Text] [Related]
20. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]